Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer

Hunan Province Tumor Hospital1 site in 1 country70 target enrollmentMarch 24, 2020

ConditionsNon Small Cell Lung Cancer

Overview

Phase: N/A
Intervention: Not specified
Conditions: Non Small Cell Lung Cancer
Sponsor: Hunan Province Tumor Hospital
Enrollment: 70
Locations: 1
Primary Endpoint: PFS
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

Detailed Description

Main enrolled criteria: Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using

Registry

clinicaltrials.gov

Start Date

March 24, 2020

End Date

March 24, 2025

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Hunan Province Tumor Hospital

Responsible Party

Principal Investigator

Yongchang Zhang

professor

Hunan Province Tumor Hospital

Eligibility Criteria

Inclusion Criteria

•≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
•HER 2 Insertion or Amplification
•First Diagnosis and Treatment
•Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody